In Reply: Five Reasons Why Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy Must Be Regarded as the New Standard of Care for Diffuse Malignant Peritoneal Mesothelioma

By Baratti D.  

Annals of Surgical Oncology, Vol. 17, Iss. 6, 2010-06 ,pp. : 1713-1714

Springer Publishing Company

Access to resources Recommend Favorite

Malignant Peritoneal Mesothelioma Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is GLUT1 Expression a Major Prognostic Factor? A Preliminary Study

By Hommell-Fontaine J.   Isaac S.   Passot G.   Decullier E.   Traverse-Glehen A.   Cotte E.   You B.   Mohamed F.   Gilly F.   Glehen O.   Berger F.  

Annals of Surgical Oncology, Vol. 20, Iss. 12, 2013-11 ,pp. : 3892-3898

Springer Publishing Company

Access to resources Recommend Favorite

Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin

By Witkamp A.J.   de Bree E.   Kaag M.M.   Boot H.   Beijnen J.H.   van Slooten G.W.   van Coevorden F.   Zoetmulder F.A.N.  

European Journal of Cancer, Vol. 37, Iss. 8, 2001-05 ,pp. : 979-984

Elsevier

Access to resources Recommend Favorite

Prognostic Indicators for Patients Undergoing Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma †

By Yan Tristan   Brun Erwin   Cerruto Carlos   Haveric Namik   Chang David   Sugarbaker Paul  

Annals of Surgical Oncology, Vol. 14, Iss. 1, 2007-01 ,pp. : 41-49

Springer Publishing Company

Access to resources Recommend Favorite

Five Reasons Why Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy Must be Regarded as the New Standard of Care for Diffuse Malignant Peritoneal

By Sugarbaker Paul  

Annals of Surgical Oncology, Vol. 17, Iss. 6, 2010-06 ,pp. : 1710-1712

Springer Publishing Company

Access to resources Recommend Favorite